Fig 3. Overall survival (OS) of epidermal growth factor receptor mutant non-small-cell lung cancer patients treated with first-line tyrosine kinase inhibitors therapy.

(A): OS between high and low baseline LMR patients; (B): OS between high and low 1-month-to-baseline ratio of LMR (MBR) patients; (C) OS between “high LMR and MBR”, “high LMR or MBR”, “low LMR and MBR” patients.